Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on...
Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on...
Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD...
Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD...
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today...
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today...
10,000 Indiegogo supporters first to try one-dimensional, virtual mobile keyboard
10,000 Indiegogo supporters first to try one-dimensional, virtual mobile keyboard
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for...
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of BioAlliance Pharma (BIO.PA), a French biopharmaceutical company developing and marketing products for...
regulated information - Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a new Pledge campaign for people with epilepsy and their loved ones. The Pledge empowers the...
regulated information - Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a new Pledge campaign for people with epilepsy and their loved ones. The Pledge empowers the...
RegeneCure announced today the start of a clinical study using the company's proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common...
RegeneCure announced today the start of a clinical study using the company's proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid for patients requiring dental implants. A common...
The Pistoia Alliance is pleased to announce the release of the HELM biomolecular representation standard software toolkit and editor under the permissive open source MIT licence. HELM (Hierarchical Editing Language for...
The Pistoia Alliance is pleased to announce the release of the HELM biomolecular representation standard software toolkit and editor under the permissive open source MIT licence. HELM (Hierarchical Editing Language for...
AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The...
AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The...
The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics...
The "Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics...
VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after...
VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after...
Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the...
Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the...
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance®. This cloud-based platform seeks to introduce significant benefits to all the key...
Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance®. This cloud-based platform seeks to introduce significant benefits to all the key...
Techne Corporation (NASDAQ: TECH) (Techne) announced today that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Bionostics is a global...
Techne Corporation (NASDAQ: TECH) (Techne) announced today that it has agreed to acquire 100% ownership of Bionostics Holdings Limited and its operating subsidiary Bionostics, Inc. (Bionostics). Bionostics is a global...
Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering. (Logo:...
Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering. (Logo:...
Research and Markets (http://www.researchandmarkets.com/research/4b8vj2/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles],...
Research and Markets (http://www.researchandmarkets.com/research/4b8vj2/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles],...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of...
On 1 June 2013, Dr Wulf Fischer-Knuppertz, took over as Chief Executive Officer (CEO) of the internationally operating biotech company BIOCRATES Life Sciences AG. He will from now on be responsible for the company's...
On 1 June 2013, Dr Wulf Fischer-Knuppertz, took over as Chief Executive Officer (CEO) of the internationally operating biotech company BIOCRATES Life Sciences AG. He will from now on be responsible for the company's...
Research and Markets (http://www.researchandmarkets.com/research/cmbgcv/north_american) has announced the addition of the "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET...
Research and Markets (http://www.researchandmarkets.com/research/cmbgcv/north_american) has announced the addition of the "North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET...
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the...
Patients with Parkinson's disease using the Boston Scientific Corporation (NYSE: BSX) Vercise™ DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and...
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled...
Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise™ DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled...
BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a second quarter 2013 dividend of $0.235 per share of common stock. The dividend is equivalent to an annualized dividend of $0.94...
BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a second quarter 2013 dividend of $0.235 per share of common stock. The dividend is equivalent to an annualized dividend of $0.94...
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked...
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Donald R. Joseph as Chief Legal Officer. Mr. Joseph brings to KaloBios almost 20 years of biopharmaceutical industry experience and has worked...
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on June 17, 2013. The investors have agreed to...
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on June 17, 2013. The investors have agreed to...
Angel Medical Systems, Inc., a privately held medical device company developing implantable technologies for heart attack detection and patient alerting, announced today that its CEO, Dr. David R. Fischell was selected as...
Angel Medical Systems, Inc., a privately held medical device company developing implantable technologies for heart attack detection and patient alerting, announced today that its CEO, Dr. David R. Fischell was selected as...
BIRMINGHAM, Ala., June 17, 2013 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Arthur J. Tipton, Ph.D., has been selected by its Board of Directors to serve as president and CEO of Southern...
BIRMINGHAM, Ala., June 17, 2013 /PRNewswire-USNewswire/ -- Southern Research Institute today announced that Arthur J. Tipton, Ph.D., has been selected by its Board of Directors to serve as president and CEO of Southern...
China, a major importer of U.S. corn grain and dried distillers grain solubles, has officially granted full regulatory import authorization for Monsanto Company's (NYSE: MON) MON 87460 trait, the biotechnology trait in...
China, a major importer of U.S. corn grain and dried distillers grain solubles, has officially granted full regulatory import authorization for Monsanto Company's (NYSE: MON) MON 87460 trait, the biotechnology trait in...
Today BioSpace, the leading life sciences employment and news website, launched the 2013-2014 BioCapital Hotbed map campaign spotlighting the life sciences community in Virginia, Maryland, Delaware and Washington D.C.
Today BioSpace, the leading life sciences employment and news website, launched the 2013-2014 BioCapital Hotbed map campaign spotlighting the life sciences community in Virginia, Maryland, Delaware and Washington D.C.
The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate. To better...
The worldwide orphan drug market is set to reach $127 billion by 2018, accounting for nearly 16 percent of total prescription drug sales, according to the recently released Orphan Drug Report 2013 from Evaluate. To better...
Cedars-Sinai Medical Center, ranked one of the best healthcare organizations in the country, recovered more than $300 million by reducing net accounts receivable days with the help of OnBase, Hyland Software's enterprise...
Cedars-Sinai Medical Center, ranked one of the best healthcare organizations in the country, recovered more than $300 million by reducing net accounts receivable days with the help of OnBase, Hyland Software's enterprise...
The Biozoom (OTC QB: BIZM) scanner is the world's first portable, hand held device for the non-invasive transdermal analysis of antioxidants and other biomarkers in the human body. It replaces expensive, time consuming...
The Biozoom (OTC QB: BIZM) scanner is the world's first portable, hand held device for the non-invasive transdermal analysis of antioxidants and other biomarkers in the human body. It replaces expensive, time consuming...
Over 550 people from across the country, including nearly 100 pancreatic cancer survivors, will participate in the Seventh Annual Pancreatic Cancer Advocacy Day on June 18, 2013 to thank Congress for passing the Recalcitrant...
Over 550 people from across the country, including nearly 100 pancreatic cancer survivors, will participate in the Seventh Annual Pancreatic Cancer Advocacy Day on June 18, 2013 to thank Congress for passing the Recalcitrant...
The ALS Therapy Development Institute (ALS TDI) will hold its 11th annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with...
The ALS Therapy Development Institute (ALS TDI) will hold its 11th annual Tri-State Trek charity cycling event on July 19-21, 2013. The Tri-State Trek is a three-day, 270 mile bike ride from Newton, MA to Greenwich, CT with...
Z Trim Holdings, Inc. (OTC Markets: ZTHO – News), a biotechnology company providing value-added ingredients to a variety of industries, today announced that it will be presenting a new meat application at this year's...
Z Trim Holdings, Inc. (OTC Markets: ZTHO – News), a biotechnology company providing value-added ingredients to a variety of industries, today announced that it will be presenting a new meat application at this year's...
During its meeting on June 5, 2013, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation, approved $10.95 million in funding for fourteen new projects between Israeli and...
During its meeting on June 5, 2013, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation, approved $10.95 million in funding for fourteen new projects between Israeli and...
AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic...
AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic...
Breezy, a portfolio company of The Trendlines Group, launched their first product this week using a platform technology enabling innovative treatment of mouth-cavity conditions. LIKE, a confectionary-based product which...
Breezy, a portfolio company of The Trendlines Group, launched their first product this week using a platform technology enabling innovative treatment of mouth-cavity conditions. LIKE, a confectionary-based product which...
Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in...
Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in...
Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC)...
Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC)...
Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a...
Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a...
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of...
Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced it has completed the acquisition of intellectual property (IP) rights related to certain proprietary innovations from the compounding pharmacy operations of...
Minimally Invasive Devices, Inc. (MID) today announced it has raised an additional $2.5 million from Radius Ventures, topping off its Series B financing at $11.5 million. The Series B originally raised $9 million in a...
Minimally Invasive Devices, Inc. (MID) today announced it has raised an additional $2.5 million from Radius Ventures, topping off its Series B financing at $11.5 million. The Series B originally raised $9 million in a...
Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, &...
Research and Markets (http://www.researchandmarkets.com/research/9rwvs2/north_america) has announced the addition of the "North America Injectable Drug Delivery Market - by Formulations [Liposomes, Microspheres, &...
QUEBEC CITY, June 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies...
QUEBEC CITY, June 17, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies...
In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin® reagent for...
In an effort to aid progress in gene therapy clinical research, representatives of Clontech laboratories, Inc. and its parent company Takara Bio Inc. announce the availability of clinical grade RetroNectin® reagent for...
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), announced today that its...
Yongye International, Inc. (NASDAQ: YONG) ("Yongye" or the "Company"), a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), announced today that its...
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced...
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Wednesday, June 26, 2013, from 8:30 a.m. to...
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Wednesday, June 26, 2013, from 8:30 a.m. to...
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel...
NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel...
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy...
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy...
Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet™, a delayed-release formulation of generic metformin, at the 73rd Scientific...
Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet™, a delayed-release formulation of generic metformin, at the 73rd Scientific...
Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick® by Amedra Pharmaceuticals LLC, for the emergency treatment of...
Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick® by Amedra Pharmaceuticals LLC, for the emergency treatment of...
Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma believes it to be a clear frustrating tactic that offers shareholders no...
Royalty Pharma notes today's announcement by Elan Corporation, plc (NYSE: ELN) that it intends to explore a sale of the Company. Royalty Pharma believes it to be a clear frustrating tactic that offers shareholders no...
Biozoom (OTC QB: BIZM) exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology. Pursuant to the joint venture...
Biozoom (OTC QB: BIZM) exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology. Pursuant to the joint venture...
Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy...
Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy...
InterMune, Inc. (NASDAQ: ITMN) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet® (pirfenidone), and that the agreement has been published in...
InterMune, Inc. (NASDAQ: ITMN) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet® (pirfenidone), and that the agreement has been published in...
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the pricing of an underwritten public offering of 50,000,000 units, each unit consisting of a fixed combination of one share of common stock and one warrant to...
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced the pricing of an underwritten public offering of 50,000,000 units, each unit consisting of a fixed combination of one share of common stock and one warrant to...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that it has closed the third and final tranche of its Series J Private Placement of Convertible Preferred Stock and Warrants (the "Series J...
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that it has closed the third and final tranche of its Series J Private Placement of Convertible Preferred Stock and Warrants (the "Series J...
The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment...
The Pittsburgh Life Sciences Greenhouse (PLSG) today announced a reduction in staff and levels of investment that were necessitated by delays in portfolio company exits caused primarily by the current overall investment...
Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the...
Eli Lilly and Company (NYSE: LLY) today announced it has stopped its Phase II study (BACC) for LY2886721, a beta secretase (BACE) inhibitor being investigated as a once daily treatment for its potential to slow the...
Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of...
Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's (ADA) call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of...
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ingo Bank has been appointed Senior Vice President and will become Chief Financial Officer on...
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ingo Bank has been appointed Senior Vice President and will become Chief Financial Officer on...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today described the steps...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today described the steps...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to...
Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to...
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of...
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of...
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI...
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call for an independent review of the safety data of incretin-based therapies. At BIPI...
Bluestar Silicones will showcase its new Silbione® silicone elastomer solutions, including low durometer liquid silicone rubber (LSR) and self-bleeding LSR, at the upcoming Medical Design & Manufacturing (MD&M) East...
Bluestar Silicones will showcase its new Silbione® silicone elastomer solutions, including low durometer liquid silicone rubber (LSR) and self-bleeding LSR, at the upcoming Medical Design & Manufacturing (MD&M) East...
Thanks to today's U.S. Supreme Court decision opening the door to greater access to genetic medicine by American patients and their health care providers, testing for genes specifically linked to breast, ovarian and...
Thanks to today's U.S. Supreme Court decision opening the door to greater access to genetic medicine by American patients and their health care providers, testing for genes specifically linked to breast, ovarian and...
IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented...
IntelliCell BioSciences, Inc. ("Company") (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell's proprietary patented...
RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced today the appointment of J. Scott Tarrant as...
RRD International, a product development company that provides expert-level strategic, regulatory and operational support to biopharmaceutical companies and investors, announced today the appointment of J. Scott Tarrant as...
Multi-million dollar investment allows for continued clinical studies on the Delivra™ Technology
Multi-million dollar investment allows for continued clinical studies on the Delivra™ Technology
Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that it has established a record date and a meeting date for the special meeting of its stockholders to consider and vote upon a proposal to adopt the previously...
Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) today announced that it has established a record date and a meeting date for the special meeting of its stockholders to consider and vote upon a proposal to adopt the previously...
Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen,...
Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen,...
Twenty-two of the nation's most enterprising researchers were named Pew Scholars in the Biomedical Sciences by The Pew Charitable Trusts today. The scholarships provide flexible funding to early-career scientists...
Twenty-two of the nation's most enterprising researchers were named Pew Scholars in the Biomedical Sciences by The Pew Charitable Trusts today. The scholarships provide flexible funding to early-career scientists...
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled...
Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the first patient has been enrolled...
NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected...
NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that its 60-patient Phase I/II clinical trial of...
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that its 60-patient Phase I/II clinical trial of...
Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA® (ustekinumab) 45 mg or 90 mg...
Results from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 3 study published today in The Lancet showed patients with active psoriatic arthritis who received either STELARA® (ustekinumab) 45 mg or 90 mg...
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Life Science Korea (LSK), a leading instrument distributor based in Seoul, South Korea. LSK has been Life Technologies' primary instrument...
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Life Science Korea (LSK), a leading instrument distributor based in Seoul, South Korea. LSK has been Life Technologies' primary instrument...
The market for mobile health (mHealth) products and services is an important area, serving as a catalyst for healthcare's evolution to dramatically alter care delivery and the patient experience. In the health system of...
The market for mobile health (mHealth) products and services is an important area, serving as a catalyst for healthcare's evolution to dramatically alter care delivery and the patient experience. In the health system of...
PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its...
PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its...
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China...
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China...
Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding...
Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding...
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with...
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with...
AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the...
AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the...
PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4...
PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4...
The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated...
The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded follow-on funding of $298,500 to Madera Biosciences, Inc. to further develop its small molecule drugs designed to clear accumulated...
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration. In this position, Ms. Liu will oversee the finance, investor relations and...
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the appointment of May Liu as its Senior Vice President, Finance and Administration. In this position, Ms. Liu will oversee the finance, investor relations and...
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the...
Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the...
Celsion Corporation (NASDAQ: CLSN) today issued the following statement regarding a blog entry posted by Alpha Exposure, Contributor, on Seeking Alpha.com:
Celsion Corporation (NASDAQ: CLSN) today issued the following statement regarding a blog entry posted by Alpha Exposure, Contributor, on Seeking Alpha.com:
For the first time in the United States, the State of Indiana has approved the opening of a facility that offers Photodynamic Therapy (PDT) and Sonodynamic Therapy (SDT). These therapies use a whole new approach from the...
For the first time in the United States, the State of Indiana has approved the opening of a facility that offers Photodynamic Therapy (PDT) and Sonodynamic Therapy (SDT). These therapies use a whole new approach from the...
Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of...
Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of...
Scotland's standing as Europe's largest and most highly regarded stem cell research community has been reaffirmed recently by announcements of funding from the UK Medical Research Council (MRC) and the British Heart...
Scotland's standing as Europe's largest and most highly regarded stem cell research community has been reaffirmed recently by announcements of funding from the UK Medical Research Council (MRC) and the British Heart...
Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky. The...
Catalent Pharma Solutions, a leading global drug delivery technology and advanced supply solutions company, has announced a major expansion of its controlled release drug manufacturing facility in Winchester, Kentucky. The...
Biozoom (OTC QB: BIZM), creator of the world's first handheld, non-invasive spectroscopic device for measuring health and wellness biofeedback, announced the opening of a strategic sales and business development office...
Biozoom (OTC QB: BIZM), creator of the world's first handheld, non-invasive spectroscopic device for measuring health and wellness biofeedback, announced the opening of a strategic sales and business development office...
Today, Zacks Investment Ideas feature highlights Features: Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), Regeneron (Nasdaq:REGN-Free Report), Celgene...
Today, Zacks Investment Ideas feature highlights Features: Market Vectors Biotech ETF (AMEX:BBH-Free Report), iShares Nasdaq Biotechnology ETF (Nasdaq:IBB-Free Report), Regeneron (Nasdaq:REGN-Free Report), Celgene...
Johnson & Johnson today named David Julius, PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the winner of the 2013 Dr. Paul Janssen Award for Biomedical Research. Dr....
Johnson & Johnson today named David Julius, PhD, chair of the Department of Physiology at the University of California, San Francisco (UCSF), the winner of the 2013 Dr. Paul Janssen Award for Biomedical Research. Dr....
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the...
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the...
